An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)

NCT02041533 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

541

Enrollment

INDUSTRY

Sponsor class

Conditions

Stage IV or Recurrent Non-Small Cell Lung Cancer

Interventions

BIOLOGICAL: Nivolumab
DRUG: Gemcitabine
DRUG: Cisplatin
DRUG: Carboplatin
DRUG: Paclitaxel
DRUG: Pemetrexed

Sponsor

Bristol-Myers Squibb

Collaborators

[object Object]